Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The Lancet Rheumatology , 2026
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Ongoing Support : Once authorized, enjoy 24/7 care coordination
Both cash pay and insurance are accepted
Your PlexusDx team discusses all available protocols during follow-up, ensuring your treatment aligns with your evolving health picture and personal tolerance
Handle in compliance with institutional biosafety guidelines
US$ 22.35
US$ 24.63
US$ 29.77
US$ 23.28
US$ 26.76
US$ 29.17
US$ 28.01
US$ 20.62
US$ 22.62
US$ 20.82
